News Releases

Pivotal Phase 3 EMPOWUR study met both co-primary endpoints, with significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p

Second abstract with data concluding vibegron does not inhibit CYP2D6, a common drug metabolism pathway, also accepted for podium presentation IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Apr. 29, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 27, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3

Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 18, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will host a conference call and live webcast

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 7, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A.

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 6, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced James Robinson , President and Chief Operating

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Feb. 22, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it has entered into a debt financing agreement

BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Feb. 13, 2019-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended

BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2018 third fiscal quarter